Human Atlas of Neonatal Development and Early Life-Immunity (HANDEL-I) The early life events that influence immune system development have implications in the development of a multitude of diseases including type 1 diabetes (T1D). The immune system is actively evolving and integrating dynamic signals from the host’s environment, not only to ward off external infection but…
University of Florida and Kings College London have secured a $3.7 million grant funded by Adaptive Biotechnologies and the Leona M. and Harry B. Helmsley Charitable Trust to profile T cell receptor sequences in Type 1 Diabetes. Congratulations to co-investigators Dr. Todd Brusko and Dr. Mark Peakman!
The Brusko Lab is currently recruiting a Postdoc to work on our NIH R01 “The CD226 and TIGIT Costimulatory Axis in Type 1 Diabetes.”
The 1-year C-peptide was significantly higher (β-cell preservation) in subjects treated with ATG versus placebo (P = 0.0003) but not in those treated with ATG/GCSF versus placebo (P = 0.031).
The Brusko Lab and collaborators are trying to better understand how genes influence T1D risk
Dr. Wen-I Yeh recently published her work on the phenotype of Treg expressing autoreactive TCR.
Dr. Laura Jacobsen, MD, recently teamed with the Brusko Lab on her review of TCR profiling in T1D.
Autoimmune diseases are called “invisible diseases” as symptoms are not seen. AI is Not Invisible is trying to help bring awareness for the 80 autoimmune diseases that can affect us.
Utilizing a patient’s own immune system to treat autoimmunity in type 1 diabetes – the Brusko Lab publishes novel methods to grow regulatory T cells from cryopreserved umbilical cord blood.
Using rare human samples made available through the nPOD program (JDRFnPOD.org), the Brusko Laboratory has new findings to report on the diversity and frequency of autoreactive lymphocytes in T1D.